BioSpace News Archive

Aytu BioPharma, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to AR101 (enzastaurin) for the treatment of Ehlers-Danlos Syndrome.

Tessera Therapeutics Adds New Executives to its Leadership Team as the Company Continues to Pioneer Gene Writing ™ Technology as New Category in Genetic Medicine.

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) in collaboration with researchers from Florida International University’s Department of Physics and Biomolecular Sciences Institute, today announced the publication of a study entitled “Lipid II Binding and Transmembrane Properties of Various Antimicrobial Lanthipeptides.”

Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the initiation of the CONTERNO study, a global, randomized Phase 3 trial of cosibelimab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of patients with non-squamous non-small cell lung cancer (NSCLC).

Foundation Medicine, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx.

PureTech Health plc today announced the presentation of preclinical proof-of-concept data at the 60th American College of Neuropsychopharmacology (ACNP) Annual Meeting.

Bruker Corporation (Nasdaq: BRKR) announced today that it has completed a new private placement of 10-year senior notes in the aggregate principal amount of $500 million to enhance its financial flexibility and fund strategic growth objectives.

Avistone Pharmaceuticals today announced it has received a strategic investment of more than $200 million led by Vivo Capital with participation from Bain Capital and Primavera Capital (collectively the “Investor Group”).

GT Biopharma, Inc. today announced that the Company’s mini-poster presentation abstract is now broadly available on the European Society for Medical Oncology (“ESMO”) Immuno-Oncology (“IO”) Congress 2021 abstracts webpage.

Financing and Board appointments provide foundation for KeifeRx to accelerate development of its pipeline of optimized tyrosine kinase inhibitors targeting neurodegenerative diseases.